XPhyto Announces Business Strategy and Milestones For 2021 Innovation to Impact
The Pharma Data
JANUARY 17, 2021
In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), a leader in the development of transdermal and sublingual drug formulations reported significant advancements in four therapeutic development programs. “2020 was a very productive year for XPhyto. About XPhyto Therapeutics Corp.
Let's personalize your content